DENVER, CO--(Marketwired - March 21, 2014) - Ulthera, Inc.
, a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications, announced today that it has acquired Cabochon Aesthetics, Inc. (Cabochon), the ninth company started by premier medical device incubator, The Foundry
. The FDA-cleared system developed by Cabochon -- used in a procedure to improve the appearance of cellulite -- will allow Ulthera to expand its technology offerings for physician practices worldwide.
The minimally invasive procedure targets the tight connective-tissue bands in the underlying structure of cellulite, known as fibrous septae. It uses an innovative precision-guided, vacuum-assisted approach to optimally release the restricting septae, improving the appearance of cellulite and providing a smoother look to the skin.
"Doctors tell us that so many of their female patients express frustration over cellulite's unwanted and stubborn dimpling effects," said Matthew Likens, president and CEO of Ulthera. "The procedure developed by Cabochon is a clinically proven solution with reproducible and reliable results. We're confident this technology will address the vast unmet need for a cellulite treatment that is both effective and highly satisfying to patients."
In Cabochon's pivotal study for FDA clearance, assessment of cellulite severity by an independent physician panel demonstrated that a single procedure significantly improved the appearance of cellulite.
CEO of Cabochon, Ben Brian, Ph. D., was enthused about positive patient responses following this procedure. "Patients' appearance satisfaction was zero percent before being treated, and climbed to 69 percent just two weeks after being treated. What's more, after three months, 85 percent of patients were satisfied, and after one year, 94 percent were satisfied. Considering so many women have concluded that cellulite is untreatable -- even with diet and exercise -- these data are very compelling."
Dr. Brian continued, "Ulthera has a proven track record of successfully commercializing the Ulthera® System -- the first-and-only energy-based device with a non-invasive lift indication -- with more than 2,000 Systems sold worldwide. This, coupled with the Company's dedication to continued clinical advancements, made bringing Cabochon under its wing a natural fit."
Likens added, "Cabochon and its signature procedure were an ideal addition to Ulthera's portfolio. First and foremost, the technology works, and second, it's a platform that fills a very clear void for our physician customers. The acquisition enhances our ability to bring value to our customers' practices and help drive even more patients through their doors."
The procedure developed by Cabochon will be discussed at the American Academy of Dermatology's (AAD) Annual Meeting, March 21-25, 2014 in Denver, in the following sessions:
- Poster Session: Multicenter Pivotal Study of the Safety and Effectiveness of Controlled Tissue Release for the Treatment of Cellulite
- Saturday, March 22, 11:55 AM MT
- Presenter: Michael S. Kaminer, MD, FAAD
- Scientific Session: Dermatologic Surgery: Cosmetic Tips and Pearls
- Sunday, March 23, 2:00 PM - 5:00 PM MT
- Speaker: William P. Coleman III, MD, FAAD
The system developed by Cabochon received FDA clearance for short-term improvement in the appearance of cellulite in the buttocks and thighs of adult females, based on three-month pivotal study data. Ulthera plans to launch the product on a limited basis in the latter part of 2014.
About Ulthera, Inc.
Ulthera, Inc. is a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications. The company's signature technology is the Ulthera® System, which is the first and only energy-based device that is FDA-cleared for use as an aesthetic treatment -- the Ultherapy® procedure -- that non-invasively lifts the eyebrow and skin on the neck and under the chin. Founded in 2004 and based in Mesa, Ariz., Ulthera is a privately held company. For more information, visit www.ultherapy.com.